ArticleKidney medicine2026
Using the Difference Between Estimated Glomerular Filtration Rate by Cystatin C and Creatinine to Improve Mortality Risk Prediction in Elderly Patients With CKD in the HUNT Study.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rationale & Objective: The discrepancy in estimated glomerular filtration rate by cystatin C (eGFRcys) versus creatinine (eGFRcr) has been used as a surrogate for sarcopenia. We studied whether this eGFRcys - eGFRcr difference could improve prediction of kidney failure versus death, which is important in the management of patients with chronic kidney disease (CKD). We hypothesized that it improved the death prediction but not that of kidney failure. Study Design: A five-year cohort study to assess prognostic accuracy. Setting & Participants: The population included 1,146 participants with creatinine (cr) and cystatin C (cys) measurements from the population-based the Nord-Trøndelag Health Study, Norway. Those aged ≤ 65 years or with estimated glomerular filtration rate (eGFR)cr ≥ 45 mL/min/1.73m Exposures: The mortality risk equation in patients with CKD (MREK) includes age, sex, eGFRcr, albuminuria, smoking status, history of stroke, diabetes, and heart failure. The kidney failure risk equation includes age, sex, eGFRcr, and albuminuria. Outcomes: Kidney failure or death at 5 years. Analytical approach: The performances of MREK and kidney failure risk equation with and without eGFR_diff (= eGFRcys - eGFRcr) were compared: calibration (likelihood ratio, Akaike information criterion, Brier score), discrimination (C-statistics), reclassification (net reclassification improvement and integrated discrimination improvement). Results: The mean ± SD age was 80 ± 7 years, 42% were men, the mean eGFRcr was 36 ± 8 and eGFR_diff was 1.04 ± 12 mL/min/1.73m Limitations: Untested generalizability in other populations. Conclusions: Including eGFR_diff into the kidney failure risk and mortality risk equations significantly improved mortality risk prediction, but not kidney failure, in patients with CKD. Serum creatinine level is influenced by many non-GFR determinants, including sarcopenia, and the discrepancy of creatinine versus cystatin C could be helpful in predialytic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.